Literature DB >> 33130942

The impact of low-volume metastasis on disease-free survival of women with early-stage cervical cancer.

Alessandro Buda1, Jvan Casarin2, Michael Mueller3, Francesco Fanfani4,5, Ignacio Zapardiel6, Liliana Mereu7, Andrea Puppo8, Elena De Ponti9, Marco Adorni10, Debora Ferrari10, Maria Luisa Gasparri11, Fabio Ghezzi2, Giovanni Scambia4,5, Andrea Papadia3,11.   

Abstract

PURPOSE: We aimed to assess the impact of low-volume metastasis (micrometastasis and isolated tumor cells) on disease-free survival (DFS) of women with early-stage cervical cancer.
METHODS: Women with clinically suspected stage 1A-IB2 (FIGO 2018 classification) disease who underwent retroperitoneal nodal staging between October 2010 and April 2018, were retrospectively analyzed. The group of women who had undergone lymphadenectomy and standard node pathologic analysis (H&E group), were compared to the group undergoing sentinel node mapping (SLN) and ultrastaging with or without lymphadenectomy (ultrastaging group). At a median follow-up of 45 months, the DFS curves were analyzed.
RESULTS: Overall, 573 patients were revised (272 in the H&E group and 302 in the ultrastaging group). Eighty-five patients presented lymph node metastasis (32 in H&E, 53 in ultrastaging). Ultrastaging protocol increased the rate of low-volume metastasis by 5.6%. Twenty patients showed exclusive micrometastasis or ITC's. Seventy-three recurrences occurred (35 in H&E, 38 in ultrastaging). Only 1 out of 53 patients in the ultrastaging group (1.9%) presented with micrometastasis recurred. The 3-year disease-free survival was 89% for the H&E group, and 88% for the ultrastaging group, respectively (p = 0.175).
CONCLUSION: Ultrastaging analysis allowed increasing the detection of low volume metastasis in women with early-stage cervical cancer. However, the type of nodal staging did not have an impact on patients' 3-year disease-free survival.

Entities:  

Keywords:  Cervical cancer; Low volume metastases; Progression-free survival; Sentinel node

Year:  2020        PMID: 33130942     DOI: 10.1007/s00432-020-03435-z

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  33 in total

1.  Establishing a sentinel lymph node mapping algorithm for the treatment of early cervical cancer.

Authors:  Beatrice Cormier; John P Diaz; Karin Shih; Rachael M Sampson; Yukio Sonoda; Kay J Park; Khaled Alektiar; Dennis S Chi; Richard R Barakat; Nadeem R Abu-Rustum
Journal:  Gynecol Oncol       Date:  2011-05-13       Impact factor: 5.482

2.  Risk of micrometastases in non-sentinel pelvic lymph nodes in cervical cancer.

Authors:  D Cibula; M Zikan; J Slama; D Fischerova; R Kocian; A Germanova; A Burgetova; L Dusek; P Dundr; M Gregova; K Nemejcova
Journal:  Gynecol Oncol       Date:  2016-07-12       Impact factor: 5.482

3.  SLN biopsy in cervical cancer patients with tumors larger than 2cm and 4cm.

Authors:  L Dostálek; M Zikan; D Fischerova; R Kocian; A Germanova; F Frühauf; L Dusek; J Slama; P Dundr; K Nemejcova; D Cibula
Journal:  Gynecol Oncol       Date:  2018-02-01       Impact factor: 5.482

4.  Prognostic significance of low volume sentinel lymph node disease in early-stage cervical cancer.

Authors:  D Cibula; N R Abu-Rustum; L Dusek; M Zikán; A Zaal; L Sevcik; G G Kenter; D Querleu; R Jach; A S Bats; G Dyduch; P Graf; J Klat; J Lacheta; C J L M Meijer; E Mery; R Verheijen; R P Zweemer
Journal:  Gynecol Oncol       Date:  2011-11-25       Impact factor: 5.482

Review 5.  Lower extremity lymphedema in patients with gynecologic malignancies.

Authors:  Kimberly Dessources; Emeline Aviki; Mario M Leitao
Journal:  Int J Gynecol Cancer       Date:  2020-01-07       Impact factor: 3.437

6.  The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center.

Authors:  Nadeem R Abu-Rustum; Kaled Alektiar; Alexia Iasonos; Gali Lev; Yukio Sonoda; Carol Aghajanian; Dennis S Chi; Richard R Barakat
Journal:  Gynecol Oncol       Date:  2006-06-05       Impact factor: 5.482

7.  A model for prediction of parametrial involvement and feasibility of less radical resection of parametrium in patients with FIGO stage IB1 cervical cancer.

Authors:  Suk-Joon Chang; Robert E Bristow; Hee-Sug Ryu
Journal:  Gynecol Oncol       Date:  2012-04-17       Impact factor: 5.482

8.  Indocyanine Green versus Radiotracer with or without Blue Dye for Sentinel Lymph Node Mapping in Stage >IB1 Cervical Cancer (>2 cm).

Authors:  Giampaolo Di Martino; Cinzia Crivellaro; Elena De Ponti; Beatrice Bussi; Andrea Papadia; Ignacio Zapardiel; Enrico Vizza; Federica Elisei; Maria Dolores Diestro; Luca Locatelli; Maria Luisa Gasparri; Paolo Di Lorenzo; Michael Mueller; Alessandro Buda
Journal:  J Minim Invasive Gynecol       Date:  2017-05-29       Impact factor: 4.137

9.  A prospective multicenter trial on sentinel lymph node biopsy in patients with early-stage cervical cancer (SENTIX).

Authors:  David Cibula; J Dusek; J Jarkovsky; P Dundr; D Querleu; A van der Zee; A Kucukmetin; R Kocian
Journal:  Int J Gynecol Cancer       Date:  2019-01       Impact factor: 3.437

Review 10.  [Sentinel lymph node biopsy in early-stage cervical cancer: current state of art].

Authors:  Vincent Balaya; Benedetta Guani; Hélène Bonsang-Kitzis; Myriam Deloménie; Charlotte Ngô; Rosa Montero Macias; Meriem Koual; Huyen-Thû Nguyen-Xuan; Anne Sophie Bats; Patrice Mathevet; Fabrice Lécuru
Journal:  Bull Cancer       Date:  2019-10-15       Impact factor: 1.276

View more
  2 in total

1.  Prognostic Significance of Clinicopathological Factors Influencing Overall Survival and Event-Free Survival of Patients with Cervical Cancer: A Systematic Review and Meta-Analysis.

Authors:  Shengwei Kang; Junxiang Wu; Jie Li; Qing Hou; Bin Tang
Journal:  Med Sci Monit       Date:  2022-03-09

2.  Lymph Node Involvement in Early-Stage Cervical Cancer: Is Lymphangiogenesis a Risk Factor? Results from the MICROCOL Study.

Authors:  Matteo Tantari; Stefano Bogliolo; Matteo Morotti; Vincent Balaya; Florent Bouttitie; Annie Buenerd; Laurent Magaud; Fabrice Lecuru; Benedetta Guani; Patrice Mathevet
Journal:  Cancers (Basel)       Date:  2022-01-02       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.